
Publications
Articles et résultats scientifiques des équipes et collaborateurs du PGNM.
À propos
Les publications du PGNM reflètent la production scientifique des équipes et des collaborateurs du laboratoire, couvrant les mécanismes fondamentaux, les modèles de maladies, les technologies et la recherche translationnelle.
2024
Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?,
Cells.
2024
The sweet side of glia-to-neuron reprogramming,
.
2024
Enhanced capacity for CaMKII signaling mitigates calcium release related contractile fatigue with high intensity exercise.,
Biochim Biophys Acta Mol Cell Res 2024 Feb; 1871(2): 119610.
2024
Decline of DNA damage response along with myogenic differentiation,
Life Sci Alliance 2024 Feb; 7(2): .
2024
Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia,
Trends in Molecular Medicine.
2024
Neuronal Autophagy: Regulations and Implications in Health and Disease.,
Cells 2024 Jan; 13(1): .
2024
Combining doxorubicin and miR-218-5p: a new strategy to fight breast cancer?,
Autophagy Reports.
2024
Impaired skeletal muscle regeneration in diabetes: From cellular and molecular mechanisms to novel treatments,
Cell Metabolism.
2024
A multiple animal and cellular models approach to study frataxin deficiency in Friedreich Ataxia,
Biochim Biophys Acta Mol Cell Res 2024 Oct; 1871(7): 119809.
2024
Genetic characterization of non-5q proximal spinal muscular atrophy in a French cohort: the place of whole exome sequencing.,
Eur J Hum Genet 2024 Jan; 32(1): 37-43.